7 research outputs found
Reactive Metabolite Trapping Screens and Potential Pitfalls: Bioactivation of a Homomorpholine and Formation of an Unstable Thiazolidine Adduct
Successful early attrition of potential
problematic compounds is
of great importance in the pharmaceutical industry. The lead compound
in a recent project targeting neuropathic pain was susceptible to
metabolic bioactivation, which produced reactive metabolites and showed
covalent binding to protein. Therefore, as a part of the backup series
for this compound several structural modifications were explored to
mediate the reactive metabolite and covalent binding risk. A homomorpholine
containing series of compounds was identified without compromising
potency. However, when these compounds were incubated with human liver
microsomes in the presence of GSH, Cys-Gly adducts were identified,
instead of intact GSH conjugates. This article examines the formation
of the Cys-Gly adduct with AZX ([M+H]<sup>+</sup> 486) as a representative
compound for this series. The AZX-Cys-Gly-adduct ([M+H]<sup>+</sup> 662) showed evidence of ring contraction by formation of a thiazolidine-glycine
and was additionally shown to be unstable. During its isolation for
structural characterization by <sup>1</sup>H NMR spectroscopy, it
was found to have decomposed to a product with [M+H]<sup>+</sup> 446.
The characterization and identification of this labile GSH-derived
adduct using LC-MS/MS and <sup>1</sup>H NMR are described, along with
observations around stability. In addition, various structurally related
trapping reagents were employed in an attempt to further investigate
the reaction mechanism along with a methoxylamine trapping experiment
to confirm the structure of the postulated reactive intermediate